Stocks Health care VIVS
NASDAQ · Health careVivoSim Labs, INC. (VIVS)
VivoSim Labs, INC. brought in $112K of revenue over the twelve months to June 30, 2026, down 21.1% from a year earlier. It posted a net loss of $12.3M. In fiscal 2026 capital spending exceeded operating cash flow by $10.8M. At June 30, 2026 it held $1.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about VivoSim Labs, INC.
- Net worth
- VivoSim Labs, INC. has a market value (market cap) of $2.3M at the latest share price, and shareholders' equity of -$2.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2026 revenue was $131K (-9.0% year on year), with a net loss of $13.8M. Over the 12 months to June 30, 2026: revenue $112K, net loss $12.3M.
- Cash flow
- In fiscal 2026 operations used $10.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- VivoSim Labs, INC.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
What VivoSim Labs, INC. does
VivoSim Labs, INC. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker VIVS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2026 | $131K | -$13.8M | -$5.35 | -$10.8M |
| 2025 | $144K | -$2.5M | -$1.70 | -$9.5M |
| 2024 | $109K | -$14.7M | -$19.25 | -$14.7M |
| 2023 | $370K | -$17.3M | -$23.82 | -$12.8M |
| 2022 | $1.5M | -$11.4M | -$15.88 | -$8.9M |
| 2021 | $0 | -$16.8M | -$29.36 | -$13.7M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where VIVS ranks in Health care
Latest SEC filings
What VivoSim Labs, INC. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 6, 2026Executive or director change8-KVivoSim Labs stockholders approved all proposals at the 2026 annual meeting, including an equity plan expansion, a potential reverse stock split, and warrant terms.
- August 21, 2026
- August 21, 2026
- August 21, 2026Proxy statement DEF 14A
- August 17, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Form PRER14A filing PRER14A
- August 12, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 51% to $18K versus the same quarter last year; diluted EPS -$0.25 versus -$1.14.
- August 10, 2026Preliminary proxy statement PRE 14A
- August 6, 2026
- July 31, 2026IPO registration S-1
Insider trades
What the people running VivoSim Labs, INC. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $2.8K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 31, 2026 | Lialin Tony SergeChief Commercial Officer | Bought | 10,000 | $2.8K |
| January 27, 2026 | Stern Adam KDirector | Received as pay | 15,000 | - |
| January 27, 2026 | Gobel DavidDirector | Received as pay | 15,000 | - |
| January 27, 2026 | Milhous Alison TjosvoldDirector | Received as pay | 15,000 | - |
| January 27, 2026 | Murphy KeithEXECUTIVE CHAIRMAN, Director | Received as pay | 15,000 | - |
| January 27, 2026 | Cohen Douglas JayDirector | Received as pay | 15,000 | - |
| November 17, 2025 | Gobel DavidDirector | Sold | 3,266 | $7.3K |
Who owns VIVS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Esousa Group Holdings LLC13G, passive with 1 related filers | 9.9% | August 17, 2026 |
Largest institutional holders
Insiders
6 insiders reported holding 111,583 shares in total, about $17.3K at the last price.
| Holder | Shares |
|---|---|
| Murphy KeithEXECUTIVE CHAIRMAN, Director | 26,053 |
| Cohen Douglas JayDirector | 20,732 |
| Stern Adam KDirector | 19,899 |
| Milhous Alison TjosvoldDirector | 19,899 |
| Gobel DavidDirector | 15,000 |
| Lialin Tony SergeChief Commercial Officer | 10,000 |
Questions about VIVS
What does VivoSim Labs, INC. do?
VivoSim Labs, INC. is a company in the Health care sector, listed on NASDAQ as VIVS. Its shares trade on NASDAQ under the ticker VIVS.
What is VivoSim Labs, INC.'s net worth?
VivoSim Labs, INC. has a market value (market cap) of $2.3M at the latest share price, and shareholders' equity of -$2.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is VivoSim Labs, INC. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $12.3M on revenue of $112K.
How much revenue does VivoSim Labs, INC. make?
Over the twelve months to June 30, 2026 VivoSim Labs, INC. reported revenue of $112K. That is 21.1% less than a year earlier.
When did VivoSim Labs, INC. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the executive or director change from October 6, 2026.
When is VivoSim Labs, INC.'s next earnings report?
VivoSim Labs, INC.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare VIVS with
Follow VIVS
Get an email when VivoSim Labs, INC. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values VivoSim Labs, INC. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.